Other Events ·
Ocugen updates investors on OCU400 Bahamas EAP approval and Phase 3 pipeline progress
OCGNOcugen, Inc.
The company disclosed that the Bahamas Regulatory Agency provided provisional approval and priority designation for its gene therapy candidate OCU400, enabling an Early Access Program (EAP) with commercial pricing. Ocugen anticipates full LARTA approval within 90 days to begin patient dosing globally, potentially generating $1-2 million per patient in revenue ahead of major market approvals. The presentation also highlighted ongoing Phase 3 trials for OCU400 targeting retinitis pigmentosa and OCU410ST for Stargardt disease, alongside the recent initiation of a Phase 3 trial for geographic atrophy (OCU410). Ocugen is a biotechnology company developing gene therapies to treat blindness.